Subtalamic nucleus potentiality as a target for deep brain stimulation in obsessive-compulsive disorder

Authors

  • Fabián Cremaschi Faculty of Medical Sciences, National University of Cuyo, Mendoza, Argentina.
  • Lucas Serrano Faculty of Medical Sciences, National University of Cuyo, Mendoza, Argentina.

DOI:

https://doi.org/10.47924/neurotarget2011280

Keywords:

Obsessive-compulsive disorder, subthalamic nucleus, deep brain stimulation

Abstract

The obsessive-compulsive disorder (OCD) represents a neuropsychiatric disease, in which the existence of a certain number of patiens with severe symptoms and resistant to the conventional pharmacological and psychological approach motivates the search of alternative therapies. In this regard, surgical subthalamic nucleus (STN) stimulation has been postulated as a possible treatment for these patients, given the fundamental role of this structure in limbic-motor integration within the fronto striatal pathways and its relationship with OCD pathophysiology. Therefore, the aim of the present article is to present the updated clinical evidence related to STN- stimulation efficacy, as well as to raise the issue about the possible adverse psychiatric events that should be carefully assessed in further studies.

Metrics

Metrics Loading ...

References

Kobak KA, Greist JH, Jefferson JW, et al. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a metaanalysis. Psychopharmacology Berl (1998) 136: 205–216.

Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev (2004) 24: 1011–1030

Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines.Prog Neuropsychopharmacol Biol Psychiatry 2006;30:400-412

Mancebo MC, Eisen JL, Pinto A, et al The Brown longitudinal obsessive compulsive study: treatments received and patient impressions of improvement. J Clin Psychiatry (2006) 67: 1713–1720.

Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive- compulsive disorder. Am J Psychiatry (2005) 162: 151–161.

Rotge JY, Guehl D, Dilharreguy B, et al. Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci. (2008) 33(5):405-12.

Moresco RM, Pietra L, Henin M, et al Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naïve patients. Neuropsychopharmacology. (2007) 32(1):197-205.

van der Wee NJ, Stevens H, Hardeman JA, et al Enhanced dopamine trans- porter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry.(2004)161(12):2201-6.

Saxena S, Gorbis E, O'Neill J, et al Rapid effects of brief intensive cognitive behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder. Mol Psychiatry. (2009) 14(2):197-205.

Lipsman N, Neimat JS, Lozano AM. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: the search for a valid target. Neurosurgery. (2007) 61(1):1- 11; discussion 11-3. Review.

Saxena S, Brody AL, Schwartz JM, Baxter LR. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry (1998) 173(35):26–38.

Mirza Y, O'Neill J, Smith EA, et al. Increased medial thalamic creatine-phosphocreatine found by proton magnetic resonance spectroscopy in children with obsessive-compulsive disorder versus major depression and healthy controls. J Child Neurol. (2006) 21(2):106-11.

Perani D, Colombo C, Bressi S, et. at. [18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry. 1995 Feb;166(2):244-50.

Huyser C, Veltman DJ, de Haan E, Boer F. Paediatric obsessive-compulsive disorder, a neurodevelopmental disorder? Evidence from neuroimaging. Neurosci Biobehav Rev. (2009) 33(6):818-30.

Greenberg BD, Gabriels LA, Malone DA Jr, et al Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry. (2010) 15(1):64-79.

Abelson JL, Curtis GC, Sagher O, Albucher RC, Harrigan M, Taylor SF .Deep brain stimulation for refractory obsessive-compulsive disorder.Biol Psychiatry (2005) 57: 510–516.

Aouizerate B, Cuny E, Martin-Guehl C, et.al. Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J Neurosurg. (2004) 101(4):682-6.

Lyons KE, Pahwa R. Long-term benefits in quality of life provided by bilateral subthalamic stimulation in patients with Parkinson disease. J Neurosurg. (2005) 103(2):252-5.

Houeto JL, Welter ML, Bejjani PB, et al Subthalamic stimulation in Parkinson disease: intraoperative predictive factors. Arch Neurol. (2003) 60(5):690-4.

Komotar RJ, Starke RM, Connolly ES, Goodman RR. Pallidal vs subthalamic deep brain stimulation for Parkinson disease. Neurosurgery. (2010) 67(4):N25-7.

Muniz AM, Liu W, Liu H, Lyons KE, Pahwa R, Nobre FF, Nadal J. Assessment of the effects of subthalamic stimulation in Parkinson disease patients by artificial neural network. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:5673-6.

Kelly VE, Israel SM, Samii A, et al Assessing the effects of subthalamic nucleus stimulation on gait and mobility in people with Parkinson disease. Disabil Rehabil. (2010) 32(11):929-36.

Umemura A, Oka Y, Okita K, et al Subthalamic nucleus stimulation for Parkinson disease with severe medication induced hallucinations or delu- sions. J Neurosurg. (2011) DOI: 10.3171/2011.2.JNS101261.

Alegret M, Junqué C, Valldeoriola F, et al Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease. Arch Neurol. (2001) 58(8):1223-7. Comment in: Arch Neurol. (2001) 58(8):1205-6.

Mallet L, Mesnage V, Houeto JL, et al Compulsions, Parkinson's disease, and stimulation. Lancet. (2002) 360 (9342):1302-4.

Fontaine D, Mattei V, Borg M, et.al. Effect of subthalamic nucleus stimulation on obsessive-compulsive disorder in a patient with Parkinson disease. Case report. J Neurosurg. (2004) 100(6):1084-6.

Seijo-Zazo E, Seijo-Fernández F, Fernández-González F, et al [A proposed new target for deep brain stimulation in obsessive-compulsive disorder]. [Article in Spanish] Rev Neurol. (2007) 45(7):424-8.

Mallet L, Polosan M, Jaafari N, et al STOC Study Group. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. (2008) 359(20):2121-34. Erratum in: N Engl J Med. (2009) 361(10):1027. Comment in: N Engl J Med. (2009) 360(9):931; author reply 932. N Engl J Med. (2009) 360(9):931-2.

Le Jeune F, Vérin M, N'Diaye K, et al French Stimulation dans le trouble obsessionnel compulsif (STOC) study group. Decrease of prefrontal metabolism after subthalamic stimulation in obsessive-compulsive disorder: a positron emission tomography study. Biol Psychiatry. (2010) 68(11):1016-22.

Schaltenbrand G, Wahren W. Atlas for stereotaxy of the human brain. 2nd ed. Stuttgart: Thieme; 1977.

Yelnik J, Percheron G. Subthalamic neurons in primates: a quantitative and comparative analysis. Neuroscience (1979) 4: 1717–43.

Williams PL, Warwick R. The ventral thalamus or subthalamus. In: Williams PL, Warwick R, editors. Gray‟s anatomy. 36th ed. Edinburgh: Churchill Livingstone (1980) 963–5.

Chang HT, Kita H, Kitai ST. The fine structure of the rat subthalamic nucleus: an electron microscopic study. J Comp Neurol (1983) 221: 113–23.

Kita H, Chang HT, Kitai ST. The morphology of intracellularly labeled rat subthalamic neurons: a light microscopic analysis. J Comp Neurol (1983) 215: 245–57.

Published

2011-11-01

How to Cite

1.
Cremaschi F, Serrano L. Subtalamic nucleus potentiality as a target for deep brain stimulation in obsessive-compulsive disorder. NeuroTarget [Internet]. 2011 Nov. 1 [cited 2024 Nov. 21];6(3):146-54. Available from: https://neurotarget.com/index.php/nt/article/view/280